SINOVAC Secures Strategic 10-Year Vaccine Partnership in Brazil Through National PDP Framework

SÃO PAULO, Nov. 25, 2025 — Sinovac Biotech Ltd. ("SINOVAC" or the "Company"), a leading global provider of biopharmaceutical products, has entered into a long-term strategic cooperation with the Brazilian Ministry of Health through two Productive Development Partnership (PDP) projects. The agreement, signed on November 24th, marks the first time a Chinese vaccine company has been integrated into Brazil's PDP framework.

Under the ten-year agreement, SINOVAC will collaborate with local partners, including the Tecpar Institute and Eurofarma, to establish a localized vaccine industry platform. The partnership involves a total supply of approximately 60 million doses of varicella and rabies vaccines, with a contract value exceeding USD 700 million the most significant international long-term supply agreement in the Company's history.

This cooperation aligns with broader bilateral public health initiatives and follows high-level institutional engagements. The signing ceremony, held at the Albert Einstein Hospital in São Paulo, was attended by senior officials including Minister of Health Alexandre Padilha, Minister of Science, Technology and Innovation Luciana Santos, and representatives from the Pan American Health Organization (PAHO) and the Brazilian Health Regulatory Agency (ANVISA).

"SINOVAC's mission is centered on contributing to resilient public health systems," stated Meng Weining, Vice President of SINOVAC. "This 10-year commitment is intended to address Brazil's national health priorities through reliable technology transfer and a stable supply of essential vaccines."

SINOVAC is set to expedite vaccine supply and localization initiatives in collaboration with Brazilian partners, establishing a specialized industrial platform. Beyond securing vaccine access within Brazil, the collaborative platform is designed to serve as a hub for supply resilience across emerging markets in the Global South.This partnership signifies a deepening of bilateral scientific cooperation, with plans to expand from vaccine production into broader biopharmaceutical research, intended to strengthen regional health infrastructure across Latin America.

About Brazil's PDP Program

The Productive Development Partnership (PDP) is a strategic initiative by the Brazilian government designed to systematically enhance national public health security. As a cornerstone of ongoing healthcare reforms, the program aims to reinforce the public health system through a comprehensive production strategy that ensures the stable supply of essential medicines. The core of the PDP framework involves collaboration with international pharmaceutical leaders possessing advanced technologies to establish localized manufacturing capabilities. Such partnership is intended to achieve self-sufficiency and secure the supply of critical health products within Brazil's Unified Health System (SUS).

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a global biopharmaceutical company headquartered in China. Guided by its mission to “Supply Vaccines to Eliminate Human Diseases,” the Company is dedicated to the research, development, manufacturing and supply of vaccines and related biological products, providing vaccine products and related solutions for disease prevention and control worldwide.

SINOVAC has a diversified vaccine portfolio across multiple disease areas, including influenza, viral hepatitis, varicella, hand, foot and mouth disease (HFMD), poliomyelitis, rabies, tetanus, and pneumococcal disease. Three of SINOVAC's vaccines have been prequalified by the World Health Organization: the inactivated hepatitis A vaccine Healive®, the Sabin-strain inactivated poliomyelitis  vaccine (sIPV), and the live attenuated varicella vaccine.

SINOVAC has extensive experience in vaccine research, development and commercialization for emerging infectious diseases and public health emergencies. The Company initiated vaccine R&D in response to major public health threats, including SARS, H5N1, H1N1, and COVID-19, and developed the world's first inactivated SARS vaccine (with Phase I clinical trials completed), China's first inactivated pandemic influenza vaccine against H5N1 (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the world's most widely used inactivated COVID-19 vaccine. Beyond its marketed portfolio, SINOVAC continues to advance its R&D pipeline, spanning combination vaccines, recombinant protein vaccines, mRNA technologies, antibody-based products, and other next-generation technologies and product platforms, while expanding its capabilities in disease prevention and biopharmaceuticals.

With a long-standing commitment to innovation and global health, SINOVAC continues to deepen collaboration with research institutions, international organizations, and local partners while expanding its global presence. Through technological collaboration, localized production, and industrial partnerships, the Company aims to improve access to high-quality vaccines across regions, better address local disease prevention and healthcare needs, and strengthen preparedness for future public health challenges.

For more information, please see the Company's website at www.sinovac.com.